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CAN PATENT PROTECTIONS
TRAMPLE CIVIL LIBERTIES?
THE ACLU CHALLENGES THE
PATENTABILITY OF BREAST
CANCER GENES
by ANN WEILBAECHER
A landmark lawsuit headed by the American Civil Liberties Union (ACLU)challenges the constitutionality and validity of patents on two human
genes linked to inherited breast and ovarian cancer, BRCA1 and BRCA2.1
According to the ACLU, gene patents “undermine the free exchange of infor-
mation and scientific freedom, bodily integrity, and women’s health.”2 The
ACLU argues that the contested gene patents create a monopoly that illegally
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limits women’s health care options, interferes with diagnostic testing, and
stifles research.3
The defendants argue that without intellectual property protection, companies
will not make the necessary financial investments to validate genetic tests for
diseases, which can cost millions of dollars.4 The defendants contend that “the
patent system has worked exactly as it was designed to do” by rewarding the
defendants’ landmark discoveries and encouraging life-saving research.5
The ACLU’s suit organized over 150,000 scientists, physicians, activists and
cancer patients as plaintiffs in the District Court for the Southern District of
New York.6 The defendants include the University of Utah Research Founda-
tion, which owns the patents, Myriad Genetics, the exclusive licensee, and the
U.S. Patent and Trademark Office (USPTO).7 If successful, this lawsuit could
have widespread effects not only on the validity of the BRCA1 and BRCA2
patents, but also on gene patents in general.8
THE MYRIAD GENETICS CONTROVERSY
Approximately 12 percent of women develop breast cancer during their lives,
and approximately 1.4 percent of women develop ovarian cancer.9 Women
who carry inherited mutations on their BRCA1 and BRCA2 genes face a
higher risk of breast cancer (from 40 to 85 percent) as well as a heightened risk
of ovarian cancer (from 15 to 40 percent).10 Diagnostic tests can determine if a
woman has a mutation on these genes, enabling her to take potentially life-
saving preventative measures such as removing her breasts or ovaries.11
Since the late 1990s, Myriad Genetics has held exclusive rights to the BRCA1
and BRCA2 gene patents and diagnostic tests.12 Under current U.S. patent
law, a gene patent owner has the exclusive right, for up to 20 years, to control
the patented gene’s use for research, diagnosis or treatment.13 The result is that
Myriad Genetics is the only company that may legally conduct or authorize
testing for the BRCA1 and BRCA2 genes.
According to the defendants, the limited exclusivity offered by patents was the
incentive that allowed the University of Utah and Myriad Genetics to develop
these diagnostic tools that “[have] helped thousands of women . . . take steps
to reduce their risk of breast and ovarian cancer.”14
11
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The ACLU, however, argues that this exclusivity has thwarted research and
access to diagnostic testing.15 Because Myriad Genetics has chosen to enforce
their licenses strictly, women who want to receive testing for these susceptibil-
ity genes must go through Myriad Genetics, which charges more than $3,000
for the diagnostic test, known as the “BRACAnalysis”.16
Additionally, the ACLU contends that because of this monopoly women do
not have the option of receiving a second opinion or of having another lab
perform the tests.17 Further, women who do not have insurance, or whose
insurance does not cover the test, do not have access to this potentially life-
saving diagnostic tool.18
In Europe, numerous research institutes and genetics societies have filed no-
tices of opposition to Myriad’s patents on the BRCA1 and BRCA2 genes.19 In
Canada, the government’s policy is to let labs infringe on Myriad’s patents,
thus allowing multiple labs to conduct the tests at lower prices.20
In the United States, the controversy received public attention last year in an
Emmy-nominated documentary called “In the Family.”21 In this documentary,
filmmaker Joanna Rudnick chronicles her own experience of making a difficult
decision when faced with a positive test result for inherited mutations on her
BRCA genes: risk dramatically increased odds of developing cancer, or have
her breasts and ovaries removed as preventive measures.22 Her film documents
the struggles she and others facing a similar decision encounter and explores
the detrimental effects of one company having a monopoly on the BRCA1 and
BRCA2 genes.23
Image of Filmmaker, Joanna Rudnick (standing), while filming “In the Family.”24
12
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According to Rudnick, “every film screening I have, someone inevitably will
ask me the question, ‘How can you patent a gene? Isn’t that a product of
nature?’ It’s been interesting to see how little awareness there is in the general
public about the fact that gene patenting is taking place.”25
She comments, “I was very hopeful when I heard that the ACLU was taking
on not only Myriad Genetics but also the U.S. Patent Office, really challenging
that gene patents are products of nature.”26
THE ETHICS OF PATENTING GENETIC MATERIAL
The ACLU lawsuit reinvigorates the public debate about the ethics of patent-
ing material so intimately connected to life. In a famous interview on April 12,
1955, journalist Edward R. Murrow, asked the inventor of the polio vaccine,
Dr. Jonas Salk, “Who owns the patent on this vaccine?” to which Dr. Salk
responded, “Well, the people, I would say. There is no patent. Can you patent
the sun?”27
In a controversial New York Times opinion piece written in 2007, Michael
Crichton, popular sci-fi writer and creator of television drama “ER,” decried
the perils of patenting genes, claiming, “YOU, or someone you love, may die
because of a gene patent.”28 “Gene patents are now used to halt research, pre-
vent medical testing and keep vital information from you and your doctor,” he
asserted.29
According to Jordan Paradise, Associate Professor at Seton Hall University
School of Law, “the ACLU lawsuit is fundamentally asking, is this something
that is patenting human life?”30 She elaborates, “on the one extreme, there are
people saying, you are patenting people and that’s akin to slavery.”31 She ex-
plains, however, that the moral and ethical arguments are not just about pat-
enting the human body but whether these patents are driving up the cost of
health care and whether people might not have access to certain information
about themselves.32
Proponents of gene patents, such as the Biotechnology Industry Organization
(BIO), contend that restricting gene patents “would do far more harm than
good to patients” because patenting and exclusive licensing practices are critical
to fostering the development of important genetic tests.33 BIO maintains that
13
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gene patents also “create incentives to promote physician and patient educa-
tion, broader insurance coverage, and improved compliance.”34
THE ACLU LAWSUIT
The ACLU seeks nothing less then to invalidate all gene patents.35 Dan
Ravicher, the Executive Director of the Public Patent Foundation, states that it
“is absolutely our intent that upon victory this will render invalid patents on
many other genes. We just had to pick one case as our case.”36
Dr. Alice Martin, a geneticist and patent lawyer in Chicago, expresses concern
that the ACLU is trying to eliminate gene patents in general, rather then sim-
ply targeting the poor licensing practices of one company, Myriad Genetics.37
“Don’t knock out the whole patent system because Myriad didn’t handle this
properly,” she says.38
The lawsuit claims that patents on the BRCA1 and BRCA2 genes and diagnos-
tic tests are unconstitutional and invalid, violating legal principles that prohibit
patents on products of nature.39 “The foundational issue of being able to pat-
ent genetic sequences is really in direct conflict with over 150 years of Supreme
Court precedent,” asserts Paradise.40
Indeed, since 1852, the U.S. Supreme Court has found that laws of nature,
products of nature, and abstract ideas are not patentable subject matter.41 Nat-
ural discoveries must remain “free to all men and reserved exclusively to
none.”42
However, the USPTO has granted gene patents since 1982.43 A 2005 study
published in Science found that around 20 percent of human genes are cur-
rently patented, corresponding to 4,382 of the 23,688 genes listed in the Na-
tional Center for Biotechnology Information’s gene database.44
While the USPTO has concluded that naturally occurring genes found in the
body are not patentable, genetic sequences that have been “isolated and puri-
fied” are.45 The USPTO’s rationale is twofold: (1) “the DNA molecule does
not occur in that isolated form in nature;”46 and (2) the purified state of syn-
thetic DNA preparations “is different from the naturally occurring
compound.”47
14
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According to patent law scholar and research fellow at New York University
School of Law, Matthew Herder, the doctrine of isolation and purification
goes back to a 1911 case, Parke-Davis.48 In that case, Justice Learned Hand
found that although adrenaline exits in the body, it does not exist in an iso-
lated and purified form in a way that scientists can use.49
The landmark Supreme Court case, Diamond v. Chakrabarty, further paved
the way for living entities to be considered patentable subject mater.50 In
1980, the Supreme Court, by a vote of 5-4, approved a patent on a genetically
engineered bacterium that had been modified to dissolve oil spills.51 This was
the first time a patent on a living organism was granted in the United States.52
The Court famously concluded that “anything under the sun that is made by
man” is patentable.53
Although the USPTO cites Chakrabarty and Parke-Davis as a rationale for
allowing gene patents, neither of these cases deals with genetic sequences.54 In
fact, according to Paradise, no Supreme Court case has specifically addressed
gene patents as patentable subject matter.55
Scientists, advocates and scholars disagree whether the step of isolating and
purifying a genetic sequence should be enough to constitute patentable subject
matter.56 According to the ACLU complaint, an “ ‘isolated and purified’
human gene performs the exact same function as a non-isolated and purified
human gene in a person’s body.”57
“This is simply not true,” asserts Martin.58 “A gene acting outside the living
state has a completely different function than in the body.”59 Martin elabo-
rates, “if I own the BCRA gene, I don’t own the gene in a human, because in a
human, it is not isolated and purified, it is part of the circular DNA.”60
In addition to genetic sequence claims, the ACLU is also challenging correla-
tion claims, that is, patents on the process of correlating the presence of a
mutated gene with an increased risk of a certain disease.61 The plaintiffs argue
that the process of comparing the association between a particular genetic se-
quence and a disease should not be patentable because it involves laws of
nature.62
According to an amicus brief filed by the American Medical Association and
four other medical organizations, “for a process [or correlation] claim that ap-
15
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plies a law of nature to be patent eligible, it also must transform an article to a
different state or thing, or use a particular machine.”63 The amicus brief as-
serts, “Myriad’s correlation claims do not require a specific machine nor trans-
form an article to a different state or thing.”64
The validity of this “machine-or-transformation” test is currently before the
Supreme Court in Bilski v. Kappos.65 Although Bilski involves a process for
hedging risk in commodities trading, the test might be applied to all process
patents including genetic diagnostic processes.66 According to Herder, the
ACLU’s correlation claims thus could be impacted by the Supreme Court’s
decision in Bilski.67
GENE PATENTS VIOLATE THE FIRST AMENDMENT
In addition to challenging whether genes constitute patentable subject matter,
the plaintiffs are the first to apply the First Amendment to a gene patent chal-
lenge.68 The lawsuit claims that patents on the BRCA1 and BRCA2 genes
limit research and the free flow of information, violating the First Amend-
ment.69 The plaintiffs argue that “providing a private company a monopoly
that has the effect of inhibiting, even completely preventing scientific inquiry,
into a field of knowledge is not permissible under the First Amendment.”70
“We should care a lot about scientists’ ability to disseminate their knowledge,”
asserts Herder.71 “People are raising concerns about whether the percentage of
false positives or false negatives is higher than it would otherwise be if competi-
tors were offering the services. And that’s a very real health care quality con-
cern.”72 A 2006 study published in the Journal of the American Medical
Association found that the Myriad diagnostic test missed mutations of 12% of
the 300 people examined from high-risk families.73
Rudnick points out that Myriad Genetics has a valuable repository of data on
people who have tested positive or negative for BRCA1 and BRCA2.74 “I be-
lieve they are no longer participating in registering that data in DNA
databases. That makes me even more concerned that really important and po-
tentially illuminating information may be out there but not shared with other
scientists who are working on this.”75
16
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Rudnick also expressed concerns about Myriad’s patents preventing women
from obtaining a second opinion.76 “If I’m going to take preventative measures
and remove my body parts, I want a second opinion. It seemed to me there
was nowhere else in medicine where you couldn’t get a second opinion, and
Myriad’s monopoly was limiting that.”77
The ACLU recently survived its first hurdle— a motion to dismiss by the
defendants.78 On Nov. 1, 2009, Judge Robert W. Sweet denied the motion
noting, “resolution of these issues will have far-reaching implications, not only
for gene-based health care and the health of millions of women facing the
specter of breast cancer, but also for the future course of biomedical
research.”79
Whether the ACLU lawsuit will ultimately prevail remains to be seen. What is
clear is that this lawsuit is reinvigorating the debate on a national scale of the
ethics and constitutionality of “patenting life” and the need to ensure accessi-
bility of genetic information and diagnostic tests to patients and researchers.
Regardless of the outcome of the case, the ACLU has brought a once obscure
concept of what constitutes patentable subject matter to the forefront of public
debates.
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